How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


A Fast Track To A Recombinant Biologic
In the latest edition of DANSK BIOTEK Bioneer has published a retrospective article about the evolution of recombinant protein production.  
Read more
In the forefront of developing new human cell models for neurodegenerative diseases

In a recent study, published by Zhang et al., the first-ever induced pluripotent stem cell-based neuronal model from patients with frontotemporal dementia 3 is described. Bioneer has played an integral role in the study. 

Read more
Bioneer is part of new groundbreaking project granted 25 MDKK by Innovation Fund Denmark

Rigshospitalet, Cook Regentec, Terumo BCT and Bioneer are partners in a novel five-year innovation project aiming at improving stem cell treatment for patients with chronic heart disease.

Read more

Meet us at:

6th FIP Pharmaceutical Sciences World Congress, 21-24 May 2017

Meet Bioneer during one of the poster sessions or presentations at the exciting congress in Stockholm, where leading pharmaceutical scientists from across the globe will discuss the medicines of the future.

Read more
BIONNALE, May 17 2017

XV. BIONNALE 2017 is the largest networking event for life sciences and healthcare industries in the German capital region, and Bioneer will be there.

Read more
Other places to meet us